Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-07-08 AccNo: 0001178913-19-001829 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-06-27 AccNo: 0001178913-19-001775 Size: 18 KB 网页链接
$Sol-gel(SLGL)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2019-05-31 AccNo: 0001178913-19-001632 Size: 704 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-31 AccNo: 0001178913-19-001634 Size: 263 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-23 AccNo: 0001178913-19-001570 Size: 290 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-22 AccNo: 0001178913-19-001565 Size: 218 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-05-16 AccNo: 0001178913-19-001531 Size: 140 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-04-16 AccNo: 0001178913-19-001150 Size: 30 KB 网页链接
$Sol-gel(SLGL)$ EFFECT - Notice of Effectiveness Filed: 2019-04-12 AccNo: 9999999995-19-000694 Size: 1 KB 网页链接
$Sol-gel(SLGL)$ F-3/A [Amend] - Registration statement by foreign private issuers Filed: 2019-04-10 AccNo: 0001178913-19-001102 Size: 530 KB 网页链接